191 related articles for article (PubMed ID: 38192023)
1. Whole-exome sequencing of Nigerian benign prostatic hyperplasia reveals increased alterations in apoptotic pathways.
White JA; Kaninjing ET; Adeniji KA; Jibrin P; Obafunwa JO; Ogo CN; Mohammed F; Popoola A; Fatiregun OA; Oluwole OP; Thorpe RJ; Karanam B; Elhussin I; Ambs S; Tang W; Davis M; Polak P; Campbell MJ; Brignole KR; Rotimi SO; Dean-Colomb W; Odedina FT; Yates C
Prostate; 2024 Apr; 84(5):460-472. PubMed ID: 38192023
[TBL] [Abstract][Full Text] [Related]
2. Whole-exome Sequencing of Nigerian Prostate Tumors from the Prostate Cancer Transatlantic Consortium (CaPTC) Reveals DNA Repair Genes Associated with African Ancestry.
White JA; Kaninjing ET; Adeniji KA; Jibrin P; Obafunwa JO; Ogo CN; Mohammed F; Popoola A; Fatiregun OA; Oluwole OP; Karanam B; Elhussin I; Ambs S; Tang W; Davis M; Polak P; Campbell MJ; Brignole KR; Rotimi SO; Dean-Colomb W; Odedina FT; Martin DN; Yates C
Cancer Res Commun; 2022 Sep; 2(9):1005-1016. PubMed ID: 36922933
[TBL] [Abstract][Full Text] [Related]
3. Genomic analysis of benign prostatic hyperplasia implicates cellular re-landscaping in disease pathogenesis.
Middleton LW; Shen Z; Varma S; Pollack AS; Gong X; Zhu S; Zhu C; Foley JW; Vennam S; Sweeney RT; Tu K; Biscocho J; Eminaga O; Nolley R; Tibshirani R; Brooks JD; West RB; Pollack JR
JCI Insight; 2019 May; 5(12):. PubMed ID: 31094703
[TBL] [Abstract][Full Text] [Related]
4. Spatial architectures of somatic mutations in normal prostate, benign prostatic hyperplasia and coexisting prostate cancer.
Chae J; Jung SH; Choi EJ; Kim JW; Kim NY; Moon SW; Lee JY; Chung YJ; Lee SH
Exp Mol Med; 2024 Feb; 56(1):168-176. PubMed ID: 38172600
[TBL] [Abstract][Full Text] [Related]
5. p53 tumour suppressor gene mutations in benign prostatic hyperplasia and prostate cancer.
Schlechte H; Lenk SV; Löning T; Schnorr D; Rudolph BD; Ditscherlein G; Loening SA
Eur Urol; 1998; 34(5):433-40. PubMed ID: 9803007
[TBL] [Abstract][Full Text] [Related]
6. The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates.
Buhigas C; Warren AY; Leung WK; Whitaker HC; Luxton HJ; Hawkins S; Kay J; Butler A; Xu Y; Woodcock DJ; Merson S; Frame FM; Sahli A; Abascal F; ; Martincorena I; Bova GS; Foster CS; Campbell P; Maitland NJ; Neal DE; Massie CE; Lynch AG; Eeles RA; Cooper CS; Wedge DC; Brewer DS
Mol Cancer; 2022 Sep; 21(1):183. PubMed ID: 36131292
[TBL] [Abstract][Full Text] [Related]
7. Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5-alpha reductase inhibitor resistance.
Jin R; Forbes CM; Miller NL; Lafin J; Strand DW; Case T; Cates JM; Liu Q; Ramirez-Solano M; Mohler JL; Matusik RJ
Prostate; 2024 Apr; 84(5):441-459. PubMed ID: 38168866
[TBL] [Abstract][Full Text] [Related]
8. CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer.
Zambra FM; Biolchi V; Brum IS; Chies JA
Hum Immunol; 2013 Aug; 74(8):1003-8. PubMed ID: 23632061
[TBL] [Abstract][Full Text] [Related]
9. Alcohol dehydrogenase expression patterns in normal prostate, benign prostatic hyperplasia, and prostatic adenocarcinoma in African American and Caucasian men.
Stamis SA; Heath EI; Lucas S; Boerner J; Slusher LB
Prostate; 2022 May; 82(6):666-675. PubMed ID: 35133686
[TBL] [Abstract][Full Text] [Related]
10. Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer.
Truong H; Breen K; Nandakumar S; Sjoberg DD; Kemel Y; Mehta N; Lenis AT; Reisz PA; Carruthers J; Benfante N; Joseph V; Khurram A; Gopalan A; Fine SW; Reuter VE; Vickers AJ; Birsoy O; Liu Y; Walsh M; Latham A; Mandelker D; Stadler ZK; Pietzak E; Ehdaie B; Touijer KA; Laudone VP; Slovin SF; Autio KA; Danila DC; Rathkopf DE; Eastham JA; Chen Y; Morris MJ; Offit K; Solit DB; Scher HI; Abida W; Robson ME; Carlo MI
Eur Urol; 2023 Jan; 83(1):29-38. PubMed ID: 36115772
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study.
Cheng HF; Tsai YF; Liu CY; Hsu CY; Lien PJ; Lin YS; Chao TC; Lai JI; Feng CJ; Chen YJ; Chen BF; Chiu JH; Tseng LM; Huang CC
Breast Cancer Res; 2023 Dec; 25(1):152. PubMed ID: 38098088
[TBL] [Abstract][Full Text] [Related]
12. Implication of DNA repair genes in prostate tumourigenesis in Indian males.
Bansal A; Soni A; Rao P; Singh LC; Mishra AK; Mohanty NK; Saxena S
Indian J Med Res; 2012 Oct; 136(4):622-32. PubMed ID: 23168703
[TBL] [Abstract][Full Text] [Related]
13. Detection of Cancer-Associated Gene Mutations in Urinary Cell-Free DNA among Prostate Cancer Patients in South Africa.
Temilola DO; Wium M; Paccez J; Salukazana AS; Rotimi SO; Otu HH; Carbone GM; Kaestner L; Cacciatore S; Zerbini LF
Genes (Basel); 2023 Sep; 14(10):. PubMed ID: 37895233
[TBL] [Abstract][Full Text] [Related]
14. TP53 mutation in prostate needle biopsies--comparison with patients follow-up.
Ecke TH; Schlechte HH; Hübsch A; Lenk SV; Schiemenz K; Rudolph BD; Miller K
Anticancer Res; 2007; 27(6B):4143-8. PubMed ID: 18225585
[TBL] [Abstract][Full Text] [Related]
15. Whole-exome sequencing demonstrates recurrent somatic copy number alterations and sporadic mutations in specialized stromal tumors of the prostate.
Pan CC; Tsuzuki T; Morii E; Fushimi H; Chen PC; Epstein JI
Hum Pathol; 2018 Jun; 76():9-16. PubMed ID: 29258903
[TBL] [Abstract][Full Text] [Related]
16. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling.
Luo J; Duggan DJ; Chen Y; Sauvageot J; Ewing CM; Bittner ML; Trent JM; Isaacs WB
Cancer Res; 2001 Jun; 61(12):4683-8. PubMed ID: 11406537
[TBL] [Abstract][Full Text] [Related]
17. Glutathione S-transferase gene variants and risk of benign prostate hyperplasia in a North Indian population.
Konwar R; Manchanda PK; Chaudhary P; Nayak VL; Singh V; Bid HK
Asian Pac J Cancer Prev; 2010; 11(2):365-70. PubMed ID: 20843117
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of histological prostatitis in men with benign prostatic hyperplasia or adenocarcinoma of the prostate presenting without urinary retention.
Edlin RS; Heyns CF; Van Vuuren SP; Zarrabi AD
S Afr J Surg; 2012 Nov; 50(4):127-30. PubMed ID: 23217554
[TBL] [Abstract][Full Text] [Related]
19. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
20. Myosin heavy chain gene expression in normal and hyperplastic human prostate tissue.
Lin VK; Wang D; Lee IL; Vasquez D; Fagelson JE; McConnell JD
Prostate; 2000 Aug; 44(3):193-203. PubMed ID: 10906735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
